Journal Article Ppublish
PubMed: 39993232 DOI: 10.1182/bloodadvances.2024013594
Changes in acute care use among people with sickle cell disease after adoption of a prescription drug monitoring program.
Blood Adv 9(12):3014-3023
Authors: Blake T McGee, Brandon K Attell, James Marton, Adrienne Harris, Brett Alfrey, Lindsey L Cohen, Angela B Snyder
Affiliations
- School of Nursing, Byrdine F. Lewis College of Nursing and Health Professions, Georgia State University, Atlanta, GA.
- Health Policy and Financing Team, Georgia Health Policy Center, Georgia State University, Atlanta, GA.
- Department of Economics, Georgia State University, Atlanta, GA.
- Department of Psychology, Georgia State University, Atlanta, GA.
Abstract
Many states require prescribers to check a prescription drug monitoring program (PDMP) database before prescribing controlled substances, which may affect access and health outcomes for individuals with sickle cell disease (SCD). Our study objective was to evaluate acute care trends before and after PDMP implementation among people with SCD. We carried out a retrospective longitudinal cohort study of 13 698 individuals with confirmed or probable SCD in the Georgia Sickle Cell Data Collection program from 2010 to 2019. Primary outcomes were monthly rates of emergency department (ED) visits per 1000 people with SCD; 3-day ED revisits per 1000 visits; inpatient discharges per 1000 people with SCD; 30-day readmissions per 100 discharges; and patient days hospitalized per 100 discharges. We observed that, at the start of the PDMP mandate, the volume of ED visits was 12.7% lower during the mandatory PDMP period (relative risk, 0.873; 95% confidence interval [CI], 0.843-0.904) compared with what pre-PDMP trends would have predicted. The 3-day ED revisits followed a similar pattern. No associations were observed with inpatient hospitalization rate. There was a 0.7% monthly increase in readmissions during the PDMP mandate (incidence rate ratio [IRR], 1.007; 95% CI, 1.002-1.013) compared with 0.1% before the PDMP (IRR, 1.001; 95% CI, 1.000-1.001). The volume of patient days was higher during the PDMP phase-in period but no different during the mandate. ED use by people with SCD decreased after PDMP implementation, and there was an uptick in the monthly rate of increase in 30-day readmissions after the PDMP mandate. Further research into the impact of opioid control policies on people with SCD is warranted.
MeSH
Cells, Anemia, Sickle Cell, Incidence, Drug Prescriptions, Pharmaceutical Preparations, Prescription Drug Monitoring Programs, Drug Monitoring, Prescriptions, Prescription Drugs, Hematologic Diseases